Saturday, December 11, 2010
Friday, December 10, 2010
Hepatic encephalopathy is subdivided in type A, B and C depending on the underlying cause.
Type A (=acute) describes hepatic encephalopathy associated with acute liver failure.
Type B (=bypass) is caused by portal-systemic shunting without associated intrinsic liver disease.
Type C (=cirrhosis) occurs in patients with cirrhosis.
Thursday, December 9, 2010
A: Diazepam and lorazepam.
Also, barbiturates, may be effective in controlling seizures because they may act synergistically with the benzodiazepines.
Important pearl to remember is: Phenytoin may not be effective against cocaine-induced seizures.
Wednesday, December 8, 2010
Tuesday, December 7, 2010
Answer: Vomitting induce volume depletion which causes hypokalemia by 3 systemic effects.
1. Volume depletion leads to secondary hyperaldosteronism, which, in turn, causes enhanced cortical collecting tubule secretion of potassium in response to enhanced sodium reabsorption.
2. Metabolic alkalosis which increases collecting tubule potassium secretion due to the decreased availability of hydrogen ions for secretion in response to sodium reabsorption.
3. Metabolic alkalosis directly enhances potassium entry into cells.
Monday, December 6, 2010
Answer: Hypokalemia
3-11% of patients may develop hypokalemia. Other adverse lab abnormalities include eosinophilia, anemia, decreased white blood cell count, elevations in liver function tests and serum bilirubin.
Sunday, December 5, 2010
Cryptococcosisis is a systemic or central nervous system (CNS) fungal infection caused by the yeast Cryptococcus neoformans . Cryptococcal infection is usually asymptomatic and self-limited. In patients with advanced HIV infection (eg, those with CD4 counts less than 100 cells/µL), Cryptococcus may cause life-threatening illness, either from a new exposure or through reactivation of a previously acquired latent infection. One of the hallmark is elevated ICP. Elevated ICP significantly increases the morbidity and mortality of cryptococcal meningitis and should be treated by the removal of CSF. The CSF opening pressure should be checked on the initial LP. LP and CSF removal should be repeated daily as needed for ICP reduction. Ventriculostomy or a ventriculoperitoneal (VP) shunt may be needed if the initial opening pressure is more than 400 mm H2O, or in refractory cases.
Recommended Reading
: EDITORIAL REVIEW: HIV-associated cryptococcal meningitis, Joseph N. Jarvis and Thomas S. Harrison, AIDS 2007, 21:2119–2129Saturday, December 4, 2010
1. Metronidazole-Induced and Wernicke Encephalopathy: Two Different Entities Sharing the Same Metabolic Pathway? (Letter) -American Journal of Neuroradiology 29:e84, October 2008
Friday, December 3, 2010
These are biggest infectious threats in view of their rising resistance and no new novel antibiotics coming in pipeline!
Thursday, December 2, 2010
Olanzapine (Zyprexa) is an antipsychotic in the thienobenzodiazepine class that blocks multiple neurotransmitters in brain. Olanzapine, relieves nausea in some patients failing to respond to the usual antiemetics. Studies have shown the effectiveness of olanzapine as an antiemetic. Olanzapine combined with a single dose of dexamethasone and a single dose of palonosetron is found to be very effective in controlling acute severe nausea.
Olanzapine as an Antiemetic in Refractory Nausea and Vomiting in Advanced Cancer - Journal of Pain and Symptom Management, Volume 25, Issue 6, Pages 578-582 (June 2003)
Wednesday, December 1, 2010
Answer:
Filgrastim (Neupogen): is a granulocyte colony-stimulating factor (G-CSF) analog used to stimulate the proliferation and differentiation of granulocytes in neutropenic patients. It can be given subcutaneously or intravenously. Usual dose is 5 mcg per kg of weight daily.
Pegfilgrastim (Neulasta): When compared to filgrastim, pegfilgrastim has an added polyethylene glycol molecule which reduces renal clearance and prolongs persistence in vivo (half life range: 46-62 hours). Pegfilgrastim can be given on the first day of chemotherapy.The effects of one dose of pegfilgrastim last fourteen days. It can only be given subcutaneously and not intravenously. The recommended dosage is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle.